Sarepta Therapeutics reported preliminary financial results for the fourth quarter and full year 2025 at J.P.'s 44th annual conference. Morgan Healthcare Conference.[1] Net revenue from product sales was $369.6 million for the fourth quarter and $1.86 billion for the full year.[1] Elevidys generated revenue of $110.4 million in the fourth quarter and $898.7 million for the full year.[1] The PMO franchise contributed $259.2 million in the fourth quarter and $965.6 million for the year.[1] As of December 31, 2025, the company had $953.8 million in cash and investments.[1] 2025 was impacted by a severe flu season that reduced Elevidys' revenue in the fourth quarter.[1] The company confirms a minimum annual Elevidys sales target of $500 million and plans to expand its pipeline in 2026.[1] There was a temporary recall of Elevidys in the third quarter of 2025 following patient deaths.[3]